Breaking News

Family Dollar Board Rejects Proposal From Dollar General
Tweet TWEET

Bayer to Present Data on Investigational Pulmonary Hypertension Compound Riociguat at ATS 2013

   Bayer to Present Data on Investigational Pulmonary Hypertension Compound
                            Riociguat at ATS 2013

PR Newswire

WAYNE, N.J., May 8, 2013

WAYNE, N.J., May 8, 2013 /PRNewswire/ -- Bayer HealthCare announced today that
data on its investigational pulmonary hypertension compound riociguat (BAY
63-2521) will be presented in a scientific forum at the American Thoracic
Society (ATS) International Conference May 17 – 22, in Philadelphia, PA.

"We are pleased that multiple new data sets from our riociguat clinical
development program in pulmonary arterial hypertension and chronic
thromboembolic pulmonary hypertension were accepted for presentation during
the ATS International Conference," said Pamela A. Cyrus, M.D., Vice President
and Head of U.S. Medical Affairs, Bayer HealthCare Pharmaceuticals. "Bayer
looks forward to the scientific exchange of these data with leading
respiratory and cardiovascular experts from around the world."

The studies to be presented are:

  oHemodynamic Assessment Of Patients With Inoperable Chronic Thromboembolic
    Pulmonary Hypertension (CTEPH) In The Phase III CHEST-1 Study

       oAbstract A3529; Oral presentation
       oMay 20, 2013, 2:30 p.m. – 2:45 p.m., Room 118 A-B-C (100 Level)
         Pennsylvania Convention Center

  oA Placebo-Controlled, Double-Blind Phase II Interaction Study To Evaluate
    Blood Pressure Following Addition Of Riociguat To Patients With
    Symptomatic Pulmonary Arterial Hypertension (PAH) Receiving Sildenafil
    (PATENT PLUS)

       oAbstract A3530; Oral presentation
       oMay 20, 2013, 2:45 p.m. – 3:00 p.m., Room 118 A-B-C (100 Level)
         Pennsylvania Convention Center

  oRiociguat for the Treatment of Pulmonary Arterial Hypertension (PAH): A
    Phase III Long-term Extension Study (PATENT-2)

       oAbstract A3531; Oral presentation
       oMay 20, 2013, 3:00 p.m. – 3:15 p.m., Room 118 A-B-C (100 Level)
         Pennsylvania Convention Center

  oBaseline Characteristics And Response To Treatment In Pretreated Versus
    Treatment-Naive Patients With Pulmonary Arterial Hypertension (PAH) In The
    Phase III PATENT-1 Study

       oAbstract A3532; Oral presentation
       oMay 20, 2013, 3:15 p.m. – 3:30 p.m., Room 118 A-B-C (100 Level)
         Pennsylvania Convention Center

  oEfficacy Of Riociguat In Pretreated Versus Treatment-Naive Patients With
    Pulmonary Arterial Hypertension (PAH) In the Phase III PATENT-1 Study

       oAbstract A3534; Oral presentation
       oMay 20, 2013, 3:45 p.m. – 4:00 p.m., Room 118 A-B-C (100 Level)
         Pennsylvania Convention Center

About Riociguat

Riociguat (BAY 63-2521), discovered and developed at the Bayer research
laboratories, is an investigational oral soluble guanylate cyclase (sGC)
stimulator that is being studied in CTEPH and PAH, as well as other forms of
pulmonary hypertension. Riociguat is an investigational agent and is not
approved by the FDA, EMA or other health authorities.

About Bayer HealthCare Pharmaceuticals Inc.

Bayer HealthCare Pharmaceuticals Inc. is the U.S.-based pharmaceuticals
business of Bayer HealthCare LLC, a subsidiary of Bayer AG. Bayer HealthCare
is one of the world's leading, innovative companies in the healthcare and
medical products industry, and combines the activities of the Animal Health,
Consumer Care, Medical Care, and Pharmaceuticals divisions. As a specialty
pharmaceutical company, Bayer HealthCare provides products for General
Medicine, Hematology, Neurology, Oncology and Women's Healthcare. The
company's aim is to discover and manufacture products that will improve human
health worldwide by diagnosing, preventing and treating diseases.

Bayer^® and the Bayer Cross^® are registered trademarks of Bayer.



Forward-Looking Statements

This release may contain forward-looking statements based on current
assumptions and forecasts made by Bayer Group or subgroup management. Various
known and unknown risks, uncertainties and other factors could lead to
material differences between the actual future results, financial situation,
development or performance of the company and the estimates given here. These
factors include those discussed in Bayer's public reports which are available
on the Bayer website at www.bayer.com. The company assumes no liability
whatsoever to update these forward-looking statements or to conform  them to
future events or developments.

Intended for U.S. media only



SOURCE Bayer HealthCare Pharmaceuticals Inc.

Website: http://www.bayer.com/
Contact: Marcy Funk, Communications, Bayer HealthCare, Telephone: (973)
305-5385, E-Mail: marcy.funk@bayer.com
 
Press spacebar to pause and continue. Press esc to stop.